[Efficacy analysis of CAG priming regimen combined with talidomide, interferon and interleukin 2 as the induction therapy for relapsed refractory acute myeloid leukemia]

Zhonghua Xue Ye Xue Za Zhi. 2016 Apr;37(4):334-6. doi: 10.3760/cma.j.issn.0253-2727.2016.04.017.
[Article in Chinese]
No abstract available

MeSH terms

  • Aclarubicin / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Cytarabine / therapeutic use
  • Granulocyte Colony-Stimulating Factor / therapeutic use
  • Humans
  • Interferons / therapeutic use*
  • Interleukin-2 / therapeutic use*
  • Leukemia, Myeloid, Acute / drug therapy*
  • Recurrence
  • Remission Induction
  • Thalidomide / therapeutic use*

Substances

  • Interleukin-2
  • Cytarabine
  • Granulocyte Colony-Stimulating Factor
  • Thalidomide
  • Aclarubicin
  • Interferons

Supplementary concepts

  • CAG protocol